Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats

Stroke

Volumn 30, Issue 6, 1999, Pages 1279-1285

  Toung, Thomas J ^a   Bhardwaj, Anish ^a   Dawson, Valina L ^a   Dawson, Ted M ^a   Traystman, Richard J ^a   Hurn, Patricia D ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Immunosuppressive agents; Microdialysis; Nitric oxide; Rats; Stroke

Indexed keywords

ARGININE; CARBON 14; CITRULLINE; DRUG VEHICLE; HALOTHANE; N(G) NITROARGININE; NITRIC OXIDE; SODIUM CHLORIDE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION;

EID: 0033027879     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.6.1279     Document Type: Article

References (43)

1. Sharkey J, and Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischemia. Nature. 1994;371:336-339.
2. Sharkey J. Crawford JH. Butcher SP. Marston HM. Tacrolimus (FK506) ameliorates skilled motor deficits produced by middle cerebral artery occlusion in rats. Stroke. 1996;27:2282-2286.
3. Yagita Y, Kitagawa K, Matsushita K, Taguchi A, Mabuchi T, Ohtsuki T, Yanagihara T, Matsumoto M. Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils. Life Sciences. 1996;59:1643-1650.
4. Drake M, Frieberg H, Boris-Moller F, Sakata K, Wieloch T. The immunosuppressant FK506 ameliorates ischaemic damage in rat brain. Acta Physiol Scand. 1996;158:155-159.
5. Tokime T, Nozaki K, Kikuchi H. Neuroprotective effect of FK506, an immunosuppressant, on transient global ischemia in gerbil. Neurosci Lett. 1996;206:81-84.
6. Tanaka K, Fukurchi Y, Nozaki H, Nagata E, Kondo K, Koyama S, Dembo T. Calcineurin inhibitor, FK506, prevents reduction in the binding capacity of cyclic AMP-dependent protein kinase in ischemic gerbil brain. J Cereb Blood Flow Metab. 1997;17:412-420.
7. Liu J, Farmer JO, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin A and FKBP-FK506 complexes. Cell. 1991;66:807-808.
8. Steiner JP, Dawson TM, Fotuhi M, Glatt CE, Snowman AM, Cohen N, Snyder SH. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature. 1992;358:584-586.
9. Dawson TM, Steiner JP, Lyons WE, Fotuhi M, Blue M, Snyder SH. The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. Neuroscience. 1994;62: 569-580.
10. Dawson TM, Stener JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. Immunosupressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA. 1993;90:9808-9812.
11. Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci. 1993;13:2651-2661.
12. Zhang J, Dawson VL, Dawson TM, Snyder SH. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science. 1994;263: 687-690.
13. Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD. Gender-Linked brain injury in experimental stroke. Stroke. 1998;29: 159-166.
14. Toung TJK, Traystman RJ, Hurn PD. Estrogen-mediated neuroprotection after experimental stroke in males. Stroke. 1998;29:1666-1670.
15. Takahashi H, Kirsch JR, Hashimoto K, London ED, Koehler RC, Traystman RJ. PPBP [4-phenyl-1-(4-phenylbutyl) peperidine] decreases brain injury after transient focal ischemia in rats. Stroke. 1996;27: 2120-2123.
16. Lin TN, Yong TH, Wu G, Khan M, Hsu CY. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke. 1993; 24:117-121.
17. Bhardwaj A, Northington FJ, Koehler RC, Steifel T, Hanley DF, Traystman, RJ. Adenosine modulates N-methyl-D-aspartate-stimulated hippocampal nitric oxide production in vivo. Stroke. 1995;26:1627-1633.
18. Bhardwaj A, Northington FJ, Ichord RN, Hanley DF, Traystman RJ, Koehler RC. Characterization of ionotropic receptor-mediated nitric oxide production in vivo in rats. Stroke. 1997;28:850-857.
19. Bhardwaj A, Northington FJ. Martin LJ, Hanley DF, Traystman RJ, Koehler RC. Characterization of metabotropic glutamate receptor-mediated nitric oxide production in vivo. J Cereb Blood Flow Metab. 1997;17:153-159.
20. Van Wylen DGL, Park TS, Rubio R, Berne RM. The effect of local infusion of adenosine and adenosine analogues on local cerebral blood flow. J Cereb Blood Flow Metab. 1989;9:556-562.
21. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2nd ed. New York, NY: Academic Press Inc; 1986.
22. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role of nitric oxide. Nature. 1990;347:768-770.
23. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, Degudicibus S, Siekierka J, Chin J, Hutchinson NI. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol. 1989;143:718-726.
24. Dawson VL, Kizushi VM, Huang PL, Snyder SH, Dawson TM. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase deficient mice. J Neurosci. 1996;16:2479-2487.
25. Conde M. Andrade J. Bedoya FJ. Santa Maria C. Sobrino F. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages: evidence of a direct effect on nitric oxide synthase activity. Immunology. 1995;84:476-481.
26. Endoh M. Maiese K. Wagner JA. Expression of the neural form of nitric oxide synthase by CA1 hippocampal neurons and other central nervous system neurons. Neuroscience. 1994;63:679-689.
27. Steiner JP, Connolly MA, Valentine HL, Hamilton GS, Dawson TM, Hester L, Synder SH. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin, cyclosporin A. Nature Med. 1997;3:421-428.
28. Cardell M, and Wieloch T. Time course of the translocation and inhibition of protein kinase C during complete cerebral ischemia in the rat. J Neurochem. 1993;61:1308-1314.
29. Hu B-R, Wieloch T. Tyrosine phosphorylation and activation of mitogen-activated protein kinase in the rat brain following transient cerebral ischemia. J Neurochem. 1994;62:1357-1367.
30. Shibasaki F, Mckeon F. Calcineurin functions in Ca(2+)-activated cell death in mammalian cells. J Cell Biol. 1995;131:735-743.
31. Brillantes, A-MB, Ondrias K, Scott A, Kobrinsky E, Ondriasova E, Moschella MC, Jayaraman T, Landers M, Erlich BE, Marks AR. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell. 1994;77:513-523.
32. Cameron AM, Steiner JP, Sabatini DM, Kaplin AI, Walensky LD, Snyder SH. Immunophilin FK506 binding protein associated with inositol 1,4,5,-triphosphate receptor modulates calcium flux. Proc Natl Acad Sci U S A. 1995;92:1784-1788.
33. Uchino H, Elmer E, Uchino K, Li PA, He QP, Smith ML, Siesjo BK. Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat. Brain Res. 1998;81:216-226.
34. Zoratti M, and Szabo I. The mitochondrial permeability transit. Biochem Biophys Acta. 1995;1241:139-176.
35. Griffiths EJ, Halestrap AP. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidylprolyl cis-trans isomerase. Biochem J. 1991;274:611-614.
36. Nishinaka Y, Sugiyama s, Yokota M, Saito H, Ozawa T. Protective effects of FK506 on ischemia/reperfusion induced myocardial damage in canine heart. J Cardiovasc Pharmacol. 1993;21:448-454.
37. Sakr MF, Zetti GM, Hassanein TI, Farghali H, Nalesnik MA, Gavaler JS, Starzl TE, van Theil DH. FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. Hepatology. 1991;13:947-951.
38. Nakai A. Kuroda S. Kristian T. Siesjo BK. The immunosuppressant drug FK506 ameliorates secondary mitochondrial dysfunction following transient focal cerebral ischemia in the rat. Neurobiol Dis. 1997;4: 288-300.
39. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in the rat hippocampus during transient focal ischemia monitored by intracerebral microdialysis. J Neurochem. 1984;43:1369-1374.
40. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem. 1984;42:1-11.
41. Bhardwaj A, Sawada M, London ED, Koehler RC, Traystman RJ, Kirsch JR. Potent σ1-receptor ligand 4-phenyl-1-(4-Phenyl) piperidine (PPBP) modulates basal and N-methyl-D-aspartate-evoked nitric oxide production in vivo. Stroke. 1998;29:2404-2411.
42. Northington FJ, Tobin JR, Koehler RC, Traystman RJ. In vivo production of nitric oxide with NMDA-induced cerebral hyperemia in newborn sheep. Am. J. Physiol. 1995;38:H215-H222.
43. Dykstra KH, Hsiao JK, Morrison PF, Bungay PM, Mefford IN, Scully MM, and Dedrick RL. Quantitative examination of tissue concentration profiles associated with microdialysis. J Neurochem. 1992;58: 931-940.